GlaxoSmithKline's COPD treatment receives positive CHMP opinion

GlaxoSmithKline (GSK) and Theravance (THRX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, has issued a positive opinion recommending marketing authorization for umeclidinium/vilanterol under the proposed brand name Anoro as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro is a combination of UMEC, a long-acting muscarinic antagonist and VI, a long-acting beta2 agonist in a single inhaler, the Ellipta. The proposed strength is UMEC/VI 55mcg / 22 mcg.

View Comments (0)